KR20160134072A - Method for providing information of prediction for recurrence of breast cancer - Google Patents
Method for providing information of prediction for recurrence of breast cancer Download PDFInfo
- Publication number
- KR20160134072A KR20160134072A KR1020150067493A KR20150067493A KR20160134072A KR 20160134072 A KR20160134072 A KR 20160134072A KR 1020150067493 A KR1020150067493 A KR 1020150067493A KR 20150067493 A KR20150067493 A KR 20150067493A KR 20160134072 A KR20160134072 A KR 20160134072A
- Authority
- KR
- South Korea
- Prior art keywords
- breast cancer
- recurrence
- aln
- suv
- ratio
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 65
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 65
- 238000000034 method Methods 0.000 title claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 claims abstract description 23
- 238000002600 positron emission tomography Methods 0.000 claims abstract description 18
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims description 12
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 12
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 11
- 208000030776 invasive breast carcinoma Diseases 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 238000002271 resection Methods 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 abstract description 14
- 238000004393 prognosis Methods 0.000 abstract description 7
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 description 20
- 201000009030 Carcinoma Diseases 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000013103 analytical ultracentrifugation Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000008155 medical solution Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 2
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010006200 Breast cancer stage II Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101100401560 Drosophila melanogaster mib1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710106014 Ubiquitin-conjugating enzyme E2 1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003702 image correction Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/502—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of breast, i.e. mammography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
- A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nuclear Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
The present invention relates to a method for providing information for predicting recurrence of breast cancer.
Breast cancer is a rapidly growing disease worldwide. According to the 2014 International Cancer Report, the incidence of breast cancer increased by 20% in 2012 compared to 2008. Korea is classified as a country with high cancer incidence along with North America and Western Europe. Breast cancer is the second most common cancer among women in Korea, following thyroid cancer. According to the Ministry of Health and Welfare's Central Cancer Registration Report, breast cancer accounts for 14.8% of total female cancer in 2011.
As interest in breast cancer has increased, the survival rate of breast cancer has been increasing due to early diagnosis by active health screening, newly developed imaging technology, and chemotherapy. However, breast cancer patients still die with a probability of close to 30%.
Therefore, it is very important to determine the optimal treatment method by selectively identifying patients who are suspected or suspected of having recurrence.
Hormonal status including HER2 (human epidermal growth factor receptor 2), MIB-1 (Mindbomb E3), histologic grade, histologic grade, axillary lymph node involvement, estrogen receptor and progesterone receptor status, ubiquitin protein ligase 1), and p53 are known to be prognostic factors of breast cancer. In addition, some of the study, the 18 F-FDG uptake of the original cancer reported as prognostic factors on FDG PET / CT bar.
However, these factors are still insufficient as a meaningful parameter for accurately predicting the recurrence of breast cancer.
The purpose of the present invention is to determine the maximum standard uptake ratio of axillary lymph nodes for primary carcinomas (FDG PET, [ 18 F] fluorodeoxyglucose positron emission tomography) data for breast cancer patients (ALN / T SUV ratio, axillary lymph node to primary tumor maximum standard uptake value ratio of the breast cancer to 0.43. The present invention also provides a method for providing information for predicting the recurrence of breast cancer.
In order to achieve the above object, the present invention provides a method for measuring the maximum standard absorption coefficient (ALN / T SUV ratio) of axillary lymph nodes for primary cancer in FDG PET ([ 18 F] fluorodeoxyglucose positron emission tomography) and a first step of comparing the maximum standard uptake value ratio of the axillary lymph node to the primary tumor to 0.43, to provide an information providing method for predicting the recurrence of breast cancer.
In the present invention, breast cancer refers to a clinical diagnosis of breast cancer and includes all specific sub-phenotypes of breast cancer. For example, the breast cancer may be selected from the group consisting of Ductal Carcinoma In Situ (DCIS), microinvasive ductal carcinoma, invasive ductal carcinoma (IDC), aqueous carcinoma, invasive lobular carcinoma, ductal carcinoma, , Breast epithelial carcinoma, male breast cancer, follicular tumors of the breast, recurrent and metastatic breast cancer, or a combination thereof.
Breast cancer is divided into
Preferably, the breast cancer patient of the present invention may be a patient with invasive ductal carcinoma (IDC). More preferably, the breast cancer patient of the present invention may be an invasive breast cancer patient having axillary lymph node metastasis.
In the present invention, recurrence means that the cancer recurs after the curative treatment for breast cancer, and includes locoregional recurrence and systemic metastasis recurrence. The local recurrence refers to the occurrence of cancer in the ipsilateral breast, pectoral muscle, and skin after the initial treatment, and recurrence refers to the development of cancer in the ipsilateral axillary lymph node, the upper clavicle, the subclavian lymph node, and the internal mammary lymph node. In addition, systemic recurrence refers to the transfer of cancer to the lungs, bones, and liver.
Since breast cancer has a high risk of recurrence after surgery, it is important to predict the recurrence prognosis accurately and determine the appropriate treatment direction according to the predicted prognosis, thereby reducing the recurrence rate and decreasing the mortality rate.
In the present invention, prediction refers to predicting medical consequences in advance, and means for estimating the recurrence of breast cancer patients for the purpose of the present invention in advance, that is, predicting the recurrence of breast cancer.
In the present invention, the prognosis includes the progression or mortality of a disease such as recurrence, metastasis, etc. of a breast cancer patient for the purpose of the present invention in anticipation of a medical cause (for example, recurrence, long-term survival possibility, disease-free survival rate etc.) do.
Meanwhile, in the present invention, positron emission tomography (PET) is one of the nuclear medicine testing methods using positron emission, in which a drug containing a radioactive isotope releasing a positron is injected into the body, followed by a positron emission tomography It refers to the method of knowing the body distribution. Specifically, PET is a non-invasive diagnostic technique that uses biomolecules such as glucose, amino acid, fatty acid and nucleic acid labeled with radioactive isotopes such as 18F, 11C, 13N, and 15O as tracers to image biochemical changes in the body to be. [ 18 F] fluorodeoxyglucose (FDG) PET (FDG PET) is the most widely used PET test, allowing direct assessment of glucose metabolism in cells. Most of the tumor cells have hyperglycemia due to overexpression of enzymes involved in glycolysis or glucose transporter proteins such as hexokinase and phosphofructokinase. In addition, the expression of glucose-6-phosphatase is decreased in most cancer cells, and FDG accumulates in the cells, thus showing more FDG accumulation than normal cells. It is known that FDG-PET imaging can differentiate between malignant and benign tumors by measuring the difference in the degree of glucose metabolism in various tumors.
Such PET is mainly used for evaluating cancer test, heart disease, brain disease, etc., and is used in the present invention to provide information for predicting the recurrence of breast cancer.
The PET is also used as a PET / CT scanner combined with a computerized tomography (CT) scanner. The PET / CT can provide more accurate image correction along with anatomical information, have.
Thus, the method of providing information of the present invention can utilize data obtained by PET, preferably PET / CT, for patients with breast cancer, such as invasive breast cancer.
Preferably, the FDG PET data of the present invention may be obtained prior to surgery for surgical resection of breast cancer patients.
In the present invention, a primary tumor is an anatomic site where a mass is formed, and refers to a site where tumor metastasis begins. In breast cancer, primary carcinoma is present in the breast.
In the present invention, the Standardized Uptake Value (SUV) is a software calculated value of the metabolic hypertension detected on a PET (or FDG PET) image. The radioactivity released per gram of tissue is measured by radioactivity administered per kilogram of body weight Of the total amount. Also, in the present invention, the maximum standard intake coefficient (SUV max ) refers to the maximum value of the standard intake coefficient.
According to the present invention, the maximum standard uptake ratio (ALN / T SUV ratio) of axillary lymph nodes to primary cancer is a parameter that can predict the recurrence of breast cancer in advance. Among patients suffering from breast cancer, The higher the patient's score, the higher the patient's score.
In a specific embodiment, pre-operative FDG PET / CT data were analyzed by univariate and multivariate analysis for patients with invasive breast cancer, and it was found that the ALN / T SUV ratio was the only independent factor in predicting relapse (Tables 1 and 2) .
In a preferred embodiment of the present invention, the above-described information providing method of the present invention determines that the possibility of recurrence of breast cancer is high when the ALN / T SUV ratio is greater than 0.43 and that the probability of recurrence of breast cancer is low when the ALN / T SUV ratio is less than 0.43 And may further include a second step.
More specifically, according to a graph of a survival free survival (RFS) over time in FIG. 2, when the ALN / T SUV ratio is 0.43 or less, the RFS is kept high, while the ALN / T SUV ratio is 0.43 , RFS was significantly reduced and the possibility of recurrence of breast cancer was very high.
As described above, the ALN / T SUV ratio of the present invention can be an independent index for predicting the recurrence of breast cancer and can be used as a method of providing information necessary for predicting recurrence as a predictive marker of recurrence of breast cancer.
Since the ALN / T SUV ratio among the FDG PET data of breast cancer patients according to the present invention can be used as an independent predictor of breast cancer recurrence, it is possible to accurately predict the recurrence prognosis of breast cancer patients and determine the appropriate treatment direction according to the predicted prognosis So that the information can be provided.
Figure 1 shows an image of a 47-year-old woman with primary breast cancer and axillary lymph node metastasis. Increased FDG uptake (SUV max 3.2) was observed in the upper part of the right breast in AC, and FDG uptake SUV max 1.5). SUV max ratio of axillary lymph node to primary cancer was 0.47 on FDG PET / CT and the RFS period was 190 days.
Figure 2 shows the results of survival analysis using the Kaplan-Meier method for invasive breast cancer with axillary lymph node metastasis. The significant statistical difference is between high primary carcinoma SUV max and low primary carcinoma SUV max (A), high ALN SUV max And low ALN SUV max (B), and between high ALN / T SUV ratio and low ALN / T SUV ratio (C).
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.
<Experimental Method>
1. Selection of patients
A medical chart of 153 IDC (invasive breast cancer) female patients with ALN (axillary lymph node) metastases enrolled from November 2010 to December 2012 was reviewed retrospectively. The Reward Chart Study (2014-04-27) was conducted with the approval of the Institutional Review Board.
Based on histologic evaluation, primary tumor size was determined as 1 cm or more on pathologic size based on pre-operative FDG PET / CT, and full-width at half maximum (FWHM) Respectively. Patients with both breast cancer and patients with neoadjuvant chemotherapy or radiotherapy were excluded from the patient group. The mean age of the patients was 50.5 ± 10.5 years (range: 30-76 years).
All patients underwent surveillance lymph node biopsy and / or breast conserving surgery with axillary lymph node dissection or modified radiation mastectomy. Post-operative systemic chemotherapy included a taxane-based therapy consisting of doxorubicin and cyclophosphamide leading to docetaxel. Radiation therapy was performed postoperatively. Hormone therapy or trastuzumab was given to hormone receptor positive or HER2-positive primary carcinoma patients. Patients returned to the clinic every six months for at least three years after initial treatment and underwent physical examination, mammography, breast ultrasound, and whole body bone scan tests. FDG PET / CT and breast MRI were performed at 1 year and 3 years after initial treatment. Patients suspected of having recurrence were subjected to further examination in addition to conventional imaging. Survival time was calculated from the first diagnosis day to the recurrence or last follow-up date. Recurrence-free survival (RFS) is defined as ipsilateral breast or locally invasive recurrence; Remote recurrence; Or breast cancer, the cause of non-breast cancer, or death due to unknown causes mentioned in previous studies. Breast cancer was determined to be recurrent or metastatic based on the evaluation of the primary care physician as reported on the medical chart.
2. 18 F- FDG PET / CT protocol
FDG PET / CT images were obtained using a Siemens Biograph mCT / 128 PET / CT scanner (Siemens Medical Solutions, Knoxville, USA). Prior to administration of 3-5 MBq / kg of 18 F-FDG, patients were fasted for at least 6 hours to achieve plasma glucose levels below 150 mg / dL. After 60 minutes of 18 F-FDG administration, CT scans were performed in two axes directions and parameters were set at 120 kVp and 50 mAs using CAUSE Dose (Siemens Medical Solutions, Knoxville, USA). FDG PET / CT images were obtained for 2 minutes per bed position from the middle to the thigh. CT images were used as transmission for attenuation correction and PET images were reconstructed into a 200 × 200 image matrix using an ordered subset expectation maximum iterative reconstruction algorithm.
3. 18 F- FDG PET / CT image analysis
Preoperative FDG PET / CT image ALN and to measure the SUV max of the original cancer, equipment software program (syngo via;. Siemens Medical Solutions , Knoxville, USA) to the hoengmyeon (transaxial) side portions, and primary to the fused image using We have drawn a spherical volume of interest (diameter ≥ 1) that is semi-automatically delineated against breast tumors. The ALN / T SUV ratio was calculated (Figure 1) after recalibration with reference to the anatomical image to avoid overlap with the background ingestion region where the relatively high intake of the sphere of interest in the axilla was avoided. ALN size was defined as the longest ALN diameter measured on pre-operative FDG PET / CT CT.
4. Immunohistochemistry
The immunohistochemical characteristics of breast cancer were confirmed by skilled breast pathologists. Briefly, pathologic tumors and ALN staging were interpreted according to guidelines recommended by the American Joint Committee on Cancer. Histologic or nuclear grade was also determined according to the modified Bloom-Richardson Grading system, in which grade 3 was positive. Allred scores of> 2 were used to define ER or PR positivity as described previously. Positive for p53 was defined as the presence of tumor cells with moderate or high scores of at least 5% staining. MIB-1 positive was defined as ≥20% staining of invasive tumor cells and HER2 positive was defined as high intensity or gene amplification stained with a receptor antibody using fluorescent in situ hybridization Was defined as the presence of at least 10% tumor cells. For the original carcinoma size, the longest primary carcinoma diameter was measured from post-operative permanent tissue.
5. Statistical Analysis
Numerical data were expressed as mean ± SD. The optimal cutoff values for the original carcinogenic SUV max , ALN SUV max , and ALN / T SUV ratios were confirmed using the reciever operating characteristic (ROC) curve for recurrence prediction. Survival analysis was performed using the Kaplan-Meier method. Univariate and multivariate analyzes were performed using the Cox proportional-hazards model. Statistical significance was defined as p <0.05. All statistical analyzes were performed using MedCalc software (version 11.4.4; MedCalc Software, Mariakerke, Belgium).
<Experimental Results>
1. Evaluation of patient characteristics
The characteristics of 119 patients are summarized in Table 1 below. The mean preoperative FDG PET / CT interval was 6.7 ± 9.4 days and the average follow-up period was 28.4 ± 9.0 months. Ten of 119 breast cancer patients underwent pre-FDG PET / CT preoperative ALN biopsy. Of the 119 patients, 118 (99.2%) received adjuvant chemotherapy and 101 (84.9%) received postoperative radiation therapy. 82 patients (68.9%) had breast cancer stage II and 37 patients (31.1%) had stage III disease. During follow-up, 102 patients (85.7%) remained disease free, and 17 patients (14.3%) recurred. Of the 17 recurred patients, 6 had local recurrence lesions and 11 had distant metastatic lesions. The mean RFS of 17 recurred IDC patients was 16.3 ± 8.6 months.
[Table 1]
2. RFS For prediction Parameter evaluation
Recurrent IDC patients had significantly higher primary carcinoma SUV max and ALN SUV max than patients who did not recur. The primary carcinoma SUV max of recurrent patients was 11.3 ± 6.7 and the primary carcinoma SUV max of 7.9 ± 4.6 (95% confidence interval [CI] difference, -6.00 to -0.83, p = 0.010). The ALN SUV max of the two groups were 6.9 ± 6.5 and 3.4 ± 4.2, respectively (95% CI, -5.86 to -1.15, p = 0.04). The ALN / T SUV ratio in the recurrent group was 0.97 ± 1.60 and the ALN / T SUV ratio in the non-relapse group was 0.45 ± 0.40 (95% CI, -0.88 to -0.16, p = 0.005). The primary tumor size and ALN size of recurrent IDC patients were not significantly different from those of original IDC patients without recurrence ( p = 0.698 and 0.068, respectively).
Using the ROC curve to predict recurrence, the optimal cutoff values for ALN and primary carcinoma SUV max were 2.2 (sensitivity, 88.2%; specificity, 56.9%; AUC, 0.738%; standard error [SE], 0.0575 ) And 11.1 (sensitivity, 52.9%, specificity, 81.4%; AUC, 0.660; SE, 0.0815). Comparisons of AUCs from ROC curves showed no significant difference between primary carcinoma SUV max , tumor SUV max , ALN SUV max and ALN / T SUV (all p > 0.05). Survival analysis using the Kaplan-Meier analysis showed a significant predisposing factor for the RFS of IDC: primary carcinoma SUV max (> 11.1), ALN SUV max (> 2.2) and ALN / T SUV ratio (Fig. 2).
Univariate analysis also showed that primary carcinoma SUV max , ALN SUV max , and ALN / T SUV ratio were significant contributors to RFS in IDC (Table 2). Clinical pathological findings, including ALN status (pN1 vs. pN2, pN3), nuclear and histological grades (I, II vs. III), ER (positive vs. negative) and MIB- Were significant sig- nificant factors for RFS. Multivariate analysis, however, showed that the ALN / T SUV ratio (4.20; 95% CI, 1.74-10.13; p = 0.002) was a significant independent predictor of RFS.
[Table 2]
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150067493A KR20160134072A (en) | 2015-05-14 | 2015-05-14 | Method for providing information of prediction for recurrence of breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150067493A KR20160134072A (en) | 2015-05-14 | 2015-05-14 | Method for providing information of prediction for recurrence of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160134072A true KR20160134072A (en) | 2016-11-23 |
Family
ID=57541646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150067493A KR20160134072A (en) | 2015-05-14 | 2015-05-14 | Method for providing information of prediction for recurrence of breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160134072A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170092011A (en) * | 2016-02-02 | 2017-08-10 | 이화여자대학교 산학협력단 | Method for predicting risk of onset of cardio-metabolic disease |
| KR20180128657A (en) * | 2017-05-24 | 2018-12-04 | 이화여자대학교 산학협력단 | Method for providing information of prediction for recurrence of breast cancer |
| KR20220048360A (en) * | 2020-10-12 | 2022-04-19 | 이화여자대학교 산학협력단 | Method for predicting the alteration of gut microbiota or the presence of intestinal inflammation by measuring the level of intestinal uptake of FDG |
-
2015
- 2015-05-14 KR KR1020150067493A patent/KR20160134072A/en active Search and Examination
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170092011A (en) * | 2016-02-02 | 2017-08-10 | 이화여자대학교 산학협력단 | Method for predicting risk of onset of cardio-metabolic disease |
| KR20180128657A (en) * | 2017-05-24 | 2018-12-04 | 이화여자대학교 산학협력단 | Method for providing information of prediction for recurrence of breast cancer |
| KR20220048360A (en) * | 2020-10-12 | 2022-04-19 | 이화여자대학교 산학협력단 | Method for predicting the alteration of gut microbiota or the presence of intestinal inflammation by measuring the level of intestinal uptake of FDG |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ming et al. | Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer | |
| Eubank et al. | 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer | |
| Son et al. | Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast | |
| Rosenbaum-Krumme et al. | 18 F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy | |
| Kitajima et al. | Preoperative risk stratification using metabolic parameters of 18 F-FDG PET/CT in patients with endometrial cancer | |
| Wang et al. | Evidence based imaging strategies for solitary pulmonary nodule | |
| Crippa et al. | 18 F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study | |
| Baltzer et al. | Computer-aided interpretation of dynamic magnetic resonance imaging reflects histopathology of invasive breast cancer | |
| Kim et al. | Metabolic parameters using 18 F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma | |
| Kim et al. | Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18 F-fluorocholine PET/MRI for primary prostate cancer characterization | |
| KR101949347B1 (en) | Method for providing information of prediction for recurrence of breast cancer | |
| Papantoniou et al. | Breast density, scintimammographic 99m Tc (V) DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC+ DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade | |
| Lee et al. | Preoperative [18 F] FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study | |
| KR101560880B1 (en) | A method to provide information for prognosis of breast cancer | |
| Chen et al. | Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT | |
| Jo et al. | Correlation of primary tumor FDG uptake with clinicopathologic prognostic factors in invasive ductal carcinoma of the breast | |
| Kim et al. | Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer | |
| KR20160134072A (en) | Method for providing information of prediction for recurrence of breast cancer | |
| Kassam et al. | A prospective feasibility study evaluating the role of multimodality imaging and liquid biopsy for response assessment in locally advanced rectal carcinoma | |
| Ulaner et al. | First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer | |
| Nunes et al. | Risk factors associated with disease-specific mortality in papillary thyroid cancer patients with distant metastases | |
| Shigematsu et al. | Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy | |
| Takagi et al. | Association between 18F-fluorodeoxyglucose-PET/CT and histological grade of uterine endometrial carcinoma | |
| Ito et al. | Volumetric comparison of positron emission tomography/computed tomography using 4′-[methyl-11C]-thiothymidine with 2-deoxy-2-18F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma | |
| Alavi | 18 Utility of F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment |